PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24995502-4	2014	Urolithin B at a concentration of 20 microM showed significant inhibition of interleukin 8 and extracellular matrix-degrading enzyme MMP-9 production.	urolithin B	0-11	matrix metallopeptidase 9	Homo sapiens	133-138
20338073-4	2010	Uro-A and Uro-B (10 microm) inhibited PGE2 production (85 and 40 %, respectively) after IL-1beta stimulation, whereas EA did not show any effect.	urolithin B	10-15	interleukin 1 beta	Homo sapiens	88-96
16506809-7	2006	The IC(50) values for the ERalpha and ERbeta binding assays were 0.4 and 0.75 microM for urolithin A; 20 and 11 microM for urolithin B; 3 and 0.02 for genistein; and 2.3 and 1 for daidzein, respectively; no binding was detected for resveratrol and enterolactone.	urolithin B	123-134	estrogen receptor 1	Homo sapiens	26-33
16506809-7	2006	The IC(50) values for the ERalpha and ERbeta binding assays were 0.4 and 0.75 microM for urolithin A; 20 and 11 microM for urolithin B; 3 and 0.02 for genistein; and 2.3 and 1 for daidzein, respectively; no binding was detected for resveratrol and enterolactone.	urolithin B	123-134	estrogen receptor 2	Homo sapiens	38-44
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	catalase	Mus musculus	128-136
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	interleukin 6	Mus musculus	280-284
34747418-5	2021	Furthermore, Uro B inhibited the expression of TLR4, IRAK4, TRAF6, IKK-beta, NF-kappaB p65, and HMGB1 in the small intestine.	urolithin B	13-18	toll-like receptor 4	Mus musculus	47-51
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	tumor necrosis factor	Mus musculus	286-295
34747418-5	2021	Furthermore, Uro B inhibited the expression of TLR4, IRAK4, TRAF6, IKK-beta, NF-kappaB p65, and HMGB1 in the small intestine.	urolithin B	13-18	interleukin-1 receptor-associated kinase 4	Mus musculus	53-58
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	interferon gamma	Mus musculus	297-306
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	interleukin 4	Mus musculus	308-312
34747418-5	2021	Furthermore, Uro B inhibited the expression of TLR4, IRAK4, TRAF6, IKK-beta, NF-kappaB p65, and HMGB1 in the small intestine.	urolithin B	13-18	TNF receptor-associated factor 6	Mus musculus	60-65
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	interleukin 1 alpha	Mus musculus	318-326
33061495-11	2020	Moreover, both Uro-A and Uro-B treatment downregulated the expression of LXRalpha and SREBP1c; involved in de novo lipogenesis while upregulating PPARalpha expression for increased fatty acid oxidation.	urolithin B	25-30	nuclear receptor subfamily 1, group H, member 3	Rattus norvegicus	73-81
34747418-5	2021	Furthermore, Uro B inhibited the expression of TLR4, IRAK4, TRAF6, IKK-beta, NF-kappaB p65, and HMGB1 in the small intestine.	urolithin B	13-18	conserved helix-loop-helix ubiquitous kinase	Mus musculus	67-75
34747418-5	2021	Furthermore, Uro B inhibited the expression of TLR4, IRAK4, TRAF6, IKK-beta, NF-kappaB p65, and HMGB1 in the small intestine.	urolithin B	13-18	high mobility group box 1	Mus musculus	96-101
34747418-6	2021	Therefore, these findings indicated that Uro B effectively weakened the injury to the small intestine and ameliorated intestinal immunity function through the downregulation of the HMGB1-TLR4-NF-kappaB pathway in aging mice.	urolithin B	41-46	high mobility group box 1	Mus musculus	181-186
34747418-6	2021	Therefore, these findings indicated that Uro B effectively weakened the injury to the small intestine and ameliorated intestinal immunity function through the downregulation of the HMGB1-TLR4-NF-kappaB pathway in aging mice.	urolithin B	41-46	toll-like receptor 4	Mus musculus	187-191
34747418-6	2021	Therefore, these findings indicated that Uro B effectively weakened the injury to the small intestine and ameliorated intestinal immunity function through the downregulation of the HMGB1-TLR4-NF-kappaB pathway in aging mice.	urolithin B	41-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	192-201
34867396-7	2021	Results: The D-gal-induced accelerated aging model in vivo demonstrated that UB could significantly ameliorate deficits in learning and memory by inhibiting the accumulation of advanced glycation end products (AGEs) and elevating the expression and activity of Cu, Zn-SOD and CAT.	urolithin B	77-79	catalase	Mus musculus	276-279
34867396-8	2021	Furthermore, UB downregulated the c-Jun N-terminal kinase (JNK) signaling pathway and prevented cytochrome c release from isolated mitochondria, thereby inhibiting neuronal apoptosis during the aging process.	urolithin B	13-15	mitogen-activated protein kinase 8	Mus musculus	34-57
34867396-8	2021	Furthermore, UB downregulated the c-Jun N-terminal kinase (JNK) signaling pathway and prevented cytochrome c release from isolated mitochondria, thereby inhibiting neuronal apoptosis during the aging process.	urolithin B	13-15	mitogen-activated protein kinase 8	Mus musculus	59-62
34867396-9	2021	More importantly, UB stimulation of aging mice activated ERK and phosphoinositide 3-kinase (PI3K), leading to neuronal survival along with Akt and p44/42 mitogen-activated protein kinase (MAPK) phosphorylation and activation.	urolithin B	18-20	mitogen-activated protein kinase 1	Mus musculus	57-60
34867396-9	2021	More importantly, UB stimulation of aging mice activated ERK and phosphoinositide 3-kinase (PI3K), leading to neuronal survival along with Akt and p44/42 mitogen-activated protein kinase (MAPK) phosphorylation and activation.	urolithin B	18-20	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	65-90
34867396-9	2021	More importantly, UB stimulation of aging mice activated ERK and phosphoinositide 3-kinase (PI3K), leading to neuronal survival along with Akt and p44/42 mitogen-activated protein kinase (MAPK) phosphorylation and activation.	urolithin B	18-20	thymoma viral proto-oncogene 1	Mus musculus	139-142
34867396-9	2021	More importantly, UB stimulation of aging mice activated ERK and phosphoinositide 3-kinase (PI3K), leading to neuronal survival along with Akt and p44/42 mitogen-activated protein kinase (MAPK) phosphorylation and activation.	urolithin B	18-20	mitogen-activated protein kinase 3	Mus musculus	147-150
35178131-9	2022	Mechanistically, urolithin B inhibited cardiomyocyte apoptosis by activating Akt/the mammalian target of rapamycin (mTOR) pathway, and the protection of urolithin B against cardiomyocyte apoptosis was compromised with Akt gene silencing.	urolithin B	17-28	AKT serine/threonine kinase 1	Homo sapiens	77-80
35178131-9	2022	Mechanistically, urolithin B inhibited cardiomyocyte apoptosis by activating Akt/the mammalian target of rapamycin (mTOR) pathway, and the protection of urolithin B against cardiomyocyte apoptosis was compromised with Akt gene silencing.	urolithin B	17-28	mechanistic target of rapamycin kinase	Homo sapiens	85-114
35178131-9	2022	Mechanistically, urolithin B inhibited cardiomyocyte apoptosis by activating Akt/the mammalian target of rapamycin (mTOR) pathway, and the protection of urolithin B against cardiomyocyte apoptosis was compromised with Akt gene silencing.	urolithin B	17-28	mechanistic target of rapamycin kinase	Homo sapiens	116-120
35178131-9	2022	Mechanistically, urolithin B inhibited cardiomyocyte apoptosis by activating Akt/the mammalian target of rapamycin (mTOR) pathway, and the protection of urolithin B against cardiomyocyte apoptosis was compromised with Akt gene silencing.	urolithin B	17-28	AKT serine/threonine kinase 1	Homo sapiens	218-221
35178131-9	2022	Mechanistically, urolithin B inhibited cardiomyocyte apoptosis by activating Akt/the mammalian target of rapamycin (mTOR) pathway, and the protection of urolithin B against cardiomyocyte apoptosis was compromised with Akt gene silencing.	urolithin B	153-164	AKT serine/threonine kinase 1	Homo sapiens	218-221
35178131-10	2022	Furthermore, urolithin B suppressed nuclear translocation of nuclear factor-kB (NF-kappaB) to facilitate nerve remodeling.	urolithin B	13-24	nuclear factor kappa B subunit 1	Homo sapiens	80-89
35178131-11	2022	Taken together, our findings suggested that UB reduced the occurrence of myocardial arrhythmias after hypoxia via regulation of the Akt/mTOR pathway and NF-kappaB nuclear translocation, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	44-46	AKT serine/threonine kinase 1	Homo sapiens	132-135
35178131-11	2022	Taken together, our findings suggested that UB reduced the occurrence of myocardial arrhythmias after hypoxia via regulation of the Akt/mTOR pathway and NF-kappaB nuclear translocation, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	44-46	mechanistic target of rapamycin kinase	Homo sapiens	136-140
35178131-11	2022	Taken together, our findings suggested that UB reduced the occurrence of myocardial arrhythmias after hypoxia via regulation of the Akt/mTOR pathway and NF-kappaB nuclear translocation, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	44-46	nuclear factor kappa B subunit 1	Homo sapiens	153-162
35178131-11	2022	Taken together, our findings suggested that UB reduced the occurrence of myocardial arrhythmias after hypoxia via regulation of the Akt/mTOR pathway and NF-kappaB nuclear translocation, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	220-222	AKT serine/threonine kinase 1	Homo sapiens	132-135
35178131-11	2022	Taken together, our findings suggested that UB reduced the occurrence of myocardial arrhythmias after hypoxia via regulation of the Akt/mTOR pathway and NF-kappaB nuclear translocation, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	220-222	nuclear factor kappa B subunit 1	Homo sapiens	153-162
33061495-11	2020	Moreover, both Uro-A and Uro-B treatment downregulated the expression of LXRalpha and SREBP1c; involved in de novo lipogenesis while upregulating PPARalpha expression for increased fatty acid oxidation.	urolithin B	25-30	sterol regulatory element binding transcription factor 1	Rattus norvegicus	86-93
33061495-11	2020	Moreover, both Uro-A and Uro-B treatment downregulated the expression of LXRalpha and SREBP1c; involved in de novo lipogenesis while upregulating PPARalpha expression for increased fatty acid oxidation.	urolithin B	25-30	peroxisome proliferator activated receptor alpha	Rattus norvegicus	146-155
31958459-10	2020	We determined that UB inhibited the phosphorylation of JAK2/STAT3 and Smad2/3 signalling molecules.	urolithin B	19-21	Janus kinase 2	Rattus norvegicus	55-59
31958459-10	2020	We determined that UB inhibited the phosphorylation of JAK2/STAT3 and Smad2/3 signalling molecules.	urolithin B	19-21	signal transducer and activator of transcription 3	Rattus norvegicus	60-65
31958459-10	2020	We determined that UB inhibited the phosphorylation of JAK2/STAT3 and Smad2/3 signalling molecules.	urolithin B	19-21	SMAD family member 2	Rattus norvegicus	70-77
31958459-11	2020	Our data suggest that UB reduces the occurrence of malignant ventricular arrhythmias after MI, which is likely associated with attenuation of ventricular structural remodelling via inactivation of the JAK2/STAT3 and Smad2/3 signalling pathway.	urolithin B	22-24	Janus kinase 2	Rattus norvegicus	201-205
31958459-11	2020	Our data suggest that UB reduces the occurrence of malignant ventricular arrhythmias after MI, which is likely associated with attenuation of ventricular structural remodelling via inactivation of the JAK2/STAT3 and Smad2/3 signalling pathway.	urolithin B	22-24	signal transducer and activator of transcription 3	Rattus norvegicus	206-211
31958459-11	2020	Our data suggest that UB reduces the occurrence of malignant ventricular arrhythmias after MI, which is likely associated with attenuation of ventricular structural remodelling via inactivation of the JAK2/STAT3 and Smad2/3 signalling pathway.	urolithin B	22-24	SMAD family member 2	Rattus norvegicus	216-221
31218741-0	2019	Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt/beta-catenin signaling.	urolithin B	0-11	catenin (cadherin associated protein), beta 1	Mus musculus	105-117
31218741-7	2019	Furthermore, UB could increase phosphorylated beta-catenin expression and block its translocation from nuclear to cytoplasm, thus inducing the inactivation of Wnt/beta-catenin signaling.	urolithin B	13-15	catenin (cadherin associated protein), beta 1	Mus musculus	46-58
31218741-7	2019	Furthermore, UB could increase phosphorylated beta-catenin expression and block its translocation from nuclear to cytoplasm, thus inducing the inactivation of Wnt/beta-catenin signaling.	urolithin B	13-15	catenin (cadherin associated protein), beta 1	Mus musculus	163-175
31218741-9	2019	In conclusion, our data demonstrated that UB could inhibit the proliferation of HCC cells in vitro and in vivo via inactivating Wnt/beta-catenin signaling, suggesting UB could be a promising candidate in the development of anticancer drugs targeting HCC.	urolithin B	42-44	catenin (cadherin associated protein), beta 1	Mus musculus	132-144
31218741-9	2019	In conclusion, our data demonstrated that UB could inhibit the proliferation of HCC cells in vitro and in vivo via inactivating Wnt/beta-catenin signaling, suggesting UB could be a promising candidate in the development of anticancer drugs targeting HCC.	urolithin B	167-169	catenin (cadherin associated protein), beta 1	Mus musculus	132-144
30668443-10	2019	More detailed mechanistic studies showed that urolithin B inhibited NF-kappaB activity by reducing the phosphorylation and degradation of IkappaBalpha.	urolithin B	46-57	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	138-150
30668443-11	2019	In addition, urolithin B suppressed the phosphorylation of JNK, ERK, and Akt, and enhanced the phosphorylation of AMPK, which is associated with anti-inflammatory and antioxidant processes.	urolithin B	13-24	mitogen-activated protein kinase 8	Mus musculus	59-62
30668443-11	2019	In addition, urolithin B suppressed the phosphorylation of JNK, ERK, and Akt, and enhanced the phosphorylation of AMPK, which is associated with anti-inflammatory and antioxidant processes.	urolithin B	13-24	mitogen-activated protein kinase 1	Mus musculus	64-67
30668443-11	2019	In addition, urolithin B suppressed the phosphorylation of JNK, ERK, and Akt, and enhanced the phosphorylation of AMPK, which is associated with anti-inflammatory and antioxidant processes.	urolithin B	13-24	thymoma viral proto-oncogene 1	Mus musculus	73-76
32575435-6	2020	Urolithin B was found to be a better MAO-A enzyme inhibitor among the tested urolithins and EA with an IC50 value of 0.88 microM, and displaying a mixed mode of inhibition.	urolithin B	0-11	monoamine oxidase A	Homo sapiens	37-42
31996327-0	2020	Urolithin B, a Gut Microbiota Metabolite, Protects against Myocardial Ischemia/Reperfusion Injury via p62/Keap1/Nrf2 Signaling Pathway.	urolithin B	0-11	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	102-105
31996327-0	2020	Urolithin B, a Gut Microbiota Metabolite, Protects against Myocardial Ischemia/Reperfusion Injury via p62/Keap1/Nrf2 Signaling Pathway.	urolithin B	0-11	Kelch-like ECH-associated protein 1	Rattus norvegicus	106-111
31996327-0	2020	Urolithin B, a Gut Microbiota Metabolite, Protects against Myocardial Ischemia/Reperfusion Injury via p62/Keap1/Nrf2 Signaling Pathway.	urolithin B	0-11	NFE2 like bZIP transcription factor 2	Rattus norvegicus	112-116
31996327-7	2020	Mechanistically, UB inhibited autophagy by activating Akt/mTOR/ULK1 pathway and protected against oxidative stress and caspase 3-dependent cell apoptosis.	urolithin B	17-19	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
31996327-7	2020	Mechanistically, UB inhibited autophagy by activating Akt/mTOR/ULK1 pathway and protected against oxidative stress and caspase 3-dependent cell apoptosis.	urolithin B	17-19	mechanistic target of rapamycin kinase	Rattus norvegicus	58-62
31996327-7	2020	Mechanistically, UB inhibited autophagy by activating Akt/mTOR/ULK1 pathway and protected against oxidative stress and caspase 3-dependent cell apoptosis.	urolithin B	17-19	unc-51 like autophagy activating kinase 1	Rattus norvegicus	63-67
31996327-7	2020	Mechanistically, UB inhibited autophagy by activating Akt/mTOR/ULK1 pathway and protected against oxidative stress and caspase 3-dependent cell apoptosis.	urolithin B	17-19	caspase 3	Rattus norvegicus	119-128
31996327-8	2020	In particular, UB induced accumulation of p62 and its interaction with Keap1, which promoted Nrf2 nuclear translocation during HR insult.	urolithin B	15-17	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	42-45
31996327-8	2020	In particular, UB induced accumulation of p62 and its interaction with Keap1, which promoted Nrf2 nuclear translocation during HR insult.	urolithin B	15-17	Kelch-like ECH-associated protein 1	Rattus norvegicus	71-76
31996327-8	2020	In particular, UB induced accumulation of p62 and its interaction with Keap1, which promoted Nrf2 nuclear translocation during HR insult.	urolithin B	15-17	NFE2 like bZIP transcription factor 2	Rattus norvegicus	93-97
31996327-9	2020	Of note, the protection of UB against superoxide production and apoptotic cell death was compromised with Nrf2 gene silencing.	urolithin B	27-29	NFE2 like bZIP transcription factor 2	Rattus norvegicus	106-110
31996327-10	2020	Taken together, our findings suggested that UB protected against myocardial IR injury at least partially via the p62/Keap1/Nrf2 signaling pathway, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	44-46	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	113-116
31996327-10	2020	Taken together, our findings suggested that UB protected against myocardial IR injury at least partially via the p62/Keap1/Nrf2 signaling pathway, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	44-46	Kelch-like ECH-associated protein 1	Rattus norvegicus	117-122
31996327-10	2020	Taken together, our findings suggested that UB protected against myocardial IR injury at least partially via the p62/Keap1/Nrf2 signaling pathway, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	44-46	NFE2 like bZIP transcription factor 2	Rattus norvegicus	123-127
31996327-10	2020	Taken together, our findings suggested that UB protected against myocardial IR injury at least partially via the p62/Keap1/Nrf2 signaling pathway, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	181-183	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	113-116
31996327-10	2020	Taken together, our findings suggested that UB protected against myocardial IR injury at least partially via the p62/Keap1/Nrf2 signaling pathway, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	181-183	Kelch-like ECH-associated protein 1	Rattus norvegicus	117-122
31996327-10	2020	Taken together, our findings suggested that UB protected against myocardial IR injury at least partially via the p62/Keap1/Nrf2 signaling pathway, which highlights the potential of UB as a novel therapy for ischemic heart disease.	urolithin B	181-183	NFE2 like bZIP transcription factor 2	Rattus norvegicus	123-127
30762936-0	2019	A Novel Candidate for Prevention and Treatment of Atherosclerosis: Urolithin B Decreases Lipid Plaque Deposition in apoE-/- Mice and Increases Early Stages of Reverse Cholesterol Transport in ox-LDL Treated Macrophages Cells.	urolithin B	67-78	apolipoprotein E	Mus musculus	116-120
30762936-6	2019	It is shown that urolithin B decreases lipid plaque deposition, both urolithin B and urolithin B sulfate modulate expression of SR-BI and ABCA1, and cholesterol efflux increases from cholesterol laden macrophages to HDL particles as well as to reverse lipid uptake by stimulated THP-1 macrophages.	urolithin B	69-80	scavenger receptor class B, member 1	Mus musculus	128-133
30762936-6	2019	It is shown that urolithin B decreases lipid plaque deposition, both urolithin B and urolithin B sulfate modulate expression of SR-BI and ABCA1, and cholesterol efflux increases from cholesterol laden macrophages to HDL particles as well as to reverse lipid uptake by stimulated THP-1 macrophages.	urolithin B	69-80	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	138-143
30668443-4	2019	STUDY DESIGN: The effects of urolithin B on the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and cytokines were examined in BV2 microglial cells using enzyme-linked immunosorbent assay (ELISA), reverse transcription polymerase chain reaction (RT-PCR), and Western blot analysis.	urolithin B	29-40	nitric oxide synthase 2, inducible	Mus musculus	62-93
30668443-4	2019	STUDY DESIGN: The effects of urolithin B on the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and cytokines were examined in BV2 microglial cells using enzyme-linked immunosorbent assay (ELISA), reverse transcription polymerase chain reaction (RT-PCR), and Western blot analysis.	urolithin B	29-40	nitric oxide synthase 2, inducible	Mus musculus	95-99
30668443-4	2019	STUDY DESIGN: The effects of urolithin B on the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and cytokines were examined in BV2 microglial cells using enzyme-linked immunosorbent assay (ELISA), reverse transcription polymerase chain reaction (RT-PCR), and Western blot analysis.	urolithin B	29-40	prostaglandin-endoperoxide synthase 2	Mus musculus	120-125
30668443-8	2019	In addition, urolithin B inhibited NO, TNF-alpha, and IL-6 production in lipoteichoic acid (LTA) or polyinosinic-polycytidylic acid (poly(I:C))-stimulated BV2 cells, suggesting that the anti-inflammatory effect of urolithin B is not confined to LPS stimulation.	urolithin B	13-24	tumor necrosis factor	Mus musculus	39-48
30668443-8	2019	In addition, urolithin B inhibited NO, TNF-alpha, and IL-6 production in lipoteichoic acid (LTA) or polyinosinic-polycytidylic acid (poly(I:C))-stimulated BV2 cells, suggesting that the anti-inflammatory effect of urolithin B is not confined to LPS stimulation.	urolithin B	13-24	interleukin 6	Mus musculus	54-58
30668443-9	2019	Urolithin B also showed an antioxidant effect by reducing intracellular reactive oxygen species (ROS) production and NADPH oxidase subunit expression, and by upregulating the antioxidant hemeoxygenase-1 expression via Nrf2/ARE signaling.	urolithin B	0-11	nuclear factor, erythroid derived 2, like 2	Mus musculus	218-222